PE20241211A1 - Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida - Google Patents

Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida

Info

Publication number
PE20241211A1
PE20241211A1 PE2024000932A PE2024000932A PE20241211A1 PE 20241211 A1 PE20241211 A1 PE 20241211A1 PE 2024000932 A PE2024000932 A PE 2024000932A PE 2024000932 A PE2024000932 A PE 2024000932A PE 20241211 A1 PE20241211 A1 PE 20241211A1
Authority
PE
Peru
Prior art keywords
dose
mosunetuzumab
lenalidomide
administered
regimen
Prior art date
Application number
PE2024000932A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Granier
Andrea Knapp
Chi-Chung Li
Carol Elaine O'hear
Enkhtsetseg Purev
michael c Wei
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of PE20241211A1 publication Critical patent/PE20241211A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024000932A 2021-10-29 2021-10-29 Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida PE20241211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Publications (1)

Publication Number Publication Date
PE20241211A1 true PE20241211A1 (es) 2024-06-06

Family

ID=86158448

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000932A PE20241211A1 (es) 2021-10-29 2021-10-29 Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida

Country Status (7)

Country Link
JP (2) JP7846761B2 (https=)
KR (1) KR20240093915A (https=)
AU (1) AU2021471006A1 (https=)
CA (1) CA3236111A1 (https=)
MX (1) MX2024005105A (https=)
PE (1) PE20241211A1 (https=)
WO (1) WO2023075798A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009843A (ja) * 2024-06-25 2026-01-21 ジェネンテック， インコーポレイテッド 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法
WO2026050474A1 (en) * 2024-08-28 2026-03-05 Genentech, Inc. Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020275415B2 (en) * 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma

Also Published As

Publication number Publication date
JP2024540044A (ja) 2024-10-31
JP7846761B2 (ja) 2026-04-15
CA3236111A1 (en) 2023-05-04
WO2023075798A9 (en) 2023-06-29
KR20240093915A (ko) 2024-06-24
AU2021471006A1 (en) 2024-05-16
MX2024005105A (es) 2024-05-14
JP2026004356A (ja) 2026-01-14
WO2023075798A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
PE20241211A1 (es) Metodos para el tratamiento de linfoma folicular recidivante/resistente con mosunetuzumab y lenalidomida
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2022525149A5 (https=)
AR113777A1 (es) Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos
JP2018522850A5 (https=)
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
JP2022509262A5 (https=)
MX2021013910A (es) Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
RU2011117293A (ru) Композиция для лечения заболевания
JP2022502508A5 (https=)
Shome et al. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa
JP2021152002A5 (https=)
JP2023501781A5 (https=)
AR125296A1 (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
AR105087A1 (es) Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona
PE20250161A1 (es) Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores
Koya et al. Fludarabine may overcome resistance to rituximab in IgM-related neuropathy
Jurczak et al. The use of Yttrium-90 Ibritumomab Tiuxetan (90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
Sawalha et al. Rituximab dosing in B cell lymphoma